Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Booster Dose (India)

This article was originally published in PharmAsia News

Executive Summary

Drug research and development is on the brink of being revolutionized by a new data-mining process known as chemoinformatics. A number of Indian pharmaceutical companies including Dr. Reddy's Laboratories, Wockhardt, Sun Pharma, Nicholas Piramal, and Ranbaxy are already beginning to take advantage of this technique. In chemoinformatics, researchers use computer software to create and search lists of thousands of chemical compounds. Scientists can then identify molecular combinations that are most promising for further development into new drugs. This technique can also help eliminate molecules with possibly toxic properties. By speeding up the chemical selection process, Indian drug manufacturers hope to gain the advantage over stiff international and generic competition. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel